Copper & Alzheimer's Disease

RArmant av139 at lafn.org
Thu Aug 14 21:29:00 EST 2003


Ian Goddard <igoddard at erols.mom> wrote in message news:<v92ojv8btt8ioq46dlpfkrb1e45nrhblt0 at 4ax.com>...
> A steady stream of research points to heavy metals (aluminum, iron,
> zinc, copper, and mercury) as possibly playing important roles in
> Alzheimer's disease. This latest study sheds light on copper: 
> 
> http://www.newscientist.com/news/news.jsp?id=ns99994045

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12890080&dopt=Abstract

J Am Geriatr Soc. 2003 Aug;51(8):1143-1148.  

Current Status of Metals as Therapeutic Targets in Alzheimer's
Disease.

Finefrock AE, Bush AI, Doraiswamy PM.

Department of Psychiatry, Duke University Medical Center, Durham,
North Carolina; Laboratory for Oxidation Biology Genetics and Aging
Unit and Department of Psychiatry, Harvard Medical School,
Massachusetts General Hospital, Charlestown, Massachusetts; and
Departments of Psychiatry and Medicine (Geriatrics) and The Center for
the Study of Aging and Human Development, Duke University Medical
Center, Durham, North Carolina.

There is accumulating evidence that interactions between beta-amyloid
and copper, iron, and zinc are associated with the pathophysiology of
Alzheimer's disease (AD). A significant dyshomeostasis of copper,
iron, and zinc has been detected, and the mismanagement of these
metals induces beta-amyloid precipitation and neurotoxicity. Chelating
agents offer a potential therapeutic solution to the neurotoxicity
induced by copper and iron dyshomeostasis. Currently, the copper and
zinc chelating agent clioquinol represents a potential therapeutic
route that may not only inhibit beta-amyloid neurotoxicity, but may
also reverse the accumulation of neocortical beta-amyloid. A Phase II
double-blind clinical trial of clioquinol with B12 supplementation
will be published soon, and the results are promising. This article
summarizes the role of transition metals in amyloidgenesis and reviews
the potential promise of chelation therapy as a treatment for AD.

PMID: 12890080



More information about the Neur-sci mailing list